In a move to shore up its antibody pipeline, Pfizer announced that it intends to buy Bioren, a privately-held biotech based in San Carlos, California. The drug giant said the small company's antibody-development technologies will help it identify new antibodies and improve those it's already developing.
- read this AP story for more